Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Clinuvel Pharmaceuticals Limited as of August 21, 2024, involving a change in voting power through securities transactions. This shift marks a significant change in the investment landscape for Clinuvel, with potential implications for investors.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
